A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Recruiting

Phase 1

Ziftomenib, Venetoclax, AzacitidineA Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06397027

Conditions

Refractory Acute Leukemia

Pediatric Relapsed

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Ziftomenib

Venetoclax

Azacitidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-02-28.